The role of PSMA PET/CT in distinguishing malignant from benign solitary bone lesions in prostate cancer patients. Shah N, Sedeh AE, Deffler C, Ng TSC, et al. Clin Imaging 2025;125:110570.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Shah N, Sedeh AE, Deffler C, Ng TSC, et al. The role of PSMA PET/CT in distinguishing malignant from benign solitary bone lesions in prostate cancer patients. Clin Imaging 2025;125:110570.
PMID: 40743786